Puma drug better than Herceptin in HER2 breast cancers: trial

(Reuters) - A mid-stage trial of Puma Biotechnology's experimental drug neratinib showed that it was more effective, given before surgery, than Herceptin, the Roche drug commonly used in women with a type of breast cancer fueled by a protein called HER2.

via Reuters: Health News Read More Here..